Krystal Biotech’s KB407 Granted Orphan Drug Designation by the FDA to Treat Patients With Cystic Fibrosis August 17, 2020http://ir.krystalbio.com/news-releases/news-release-details/krystal-biotechs-kb407-granted-orphan-drug-designation-fda-treat Krystal Biotech’s KB407 Granted Orphan Drug Designation by the FDA to Treat Patients With Cystic Fibrosis